The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.
His remarks come after the U.S. drugmaker Merck & Co. Inc. (NYSE:MRK) announced it would cancel its planned around $1.36 billion (1 billion Sterling pounds) London research center, citing Britain's slow progress on life sciences investment and the undervaluation of innovative medicines by successive governments.
